Imagine a school system forced to make a heart-wrenching decision: prioritize its budget or continue supporting employees' health journeys. That's the reality facing Howard County schools, which recently spent a staggering $8.2 million on weight-loss medications, only to abruptly halt coverage. This dramatic move highlights the skyrocketing costs of popular drugs like Wegovy, Mounjaro, and Ozempic, originally designed for diabetes but increasingly prescribed for weight loss.
But here's where it gets controversial: while these medications offer life-changing benefits for many, their soaring costs are putting a stranglehold on employer-sponsored health plans. Howard County's experience isn't unique. A growing number of employers are scaling back coverage, leaving employees facing difficult choices.
The numbers are eye-opening. In just nine months of 2025, Howard County's spending on these drugs, known as GLP-1 agonists, surged by $6.6 million, covering 1,144 prescriptions – nearly 10% of their workforce. This exponential growth, a 600% increase in two years, forced the school system to act. Starting March 31, coverage will be limited to those with diabetes, preventing a nearly 20% hike in health insurance premiums for everyone.
This decision raises crucial questions. Should employers bear the brunt of these expensive medications, even if they're not originally intended for weight loss? And this is the part most people miss: GLP-1 agonists aren't just about shedding pounds. For individuals like a Howard County special education teacher, they're a lifeline. Prescribed Wegovy for prediabetes, she experienced improved blood sugar control, significant weight loss, and increased energy. Now facing the prospect of paying hundreds of dollars monthly out-of-pocket, she fears losing the progress she's made.
Dr. Jung-Im Shin, from Johns Hopkins Bloomberg School of Public Health, emphasizes the preventative power of these drugs for obesity, potentially staving off diabetes and its devastating complications. But, she warns, restricting access could lead to delayed treatment and worsened health outcomes.
The debate rages on. While CVS Caremark, the school system's prescription benefits manager, remains silent, experts like Lynne Cotter from KFF point to the fluctuating prices of these drugs as a major factor. Employers often pay higher prices than individuals, adding to the financial strain.
KFF's 2025 employer health benefits survey reveals a growing number of large companies covering GLP-1s for weight loss, but many are reconsidering due to cost concerns.
The future of GLP-1 coverage remains uncertain. As Cotter aptly states, “The story on GLP-1s is not yet written.” It's a complex issue with no easy answers, pitting financial responsibility against employee well-being.
What do you think? Should employers prioritize budget stability or continue covering these potentially life-changing medications? Share your thoughts in the comments below.
